Ferlin overview: from membrane to cancer biology by Peulen, Olivier et al.
 Cells 2019, 8, 954; doi:10.3390/cells8090954 www.mdpi.com/journal/cells 
Review 
Ferlin Overview: From Membrane to Cancer Biology 
Olivier Peulen 1,*, Gilles Rademaker 1, Sandy Anania 1, Andrei Turtoi 2,3,4, Akeila Bellahcène 1  
and Vincent Castronovo 1 
1 Metastasis Research Laboratory, Giga Cancer, University of Liège, B4000 Liège, Belgium 
2 Tumor Microenvironment Laboratory, Institut de Recherche en Cancérologie de Montpellier,  
INSERM U1194, 34000 Montpellier, France 
3 Institut du Cancer de Montpeiller, 34000 Montpellier, France 
4 Université de Montpellier, 34000 Montpellier, France 
* Correspondence: olivier.peulen@uliege.be; Tel.: +32-4-366-37-92 
Received: 8 August 2019; Accepted: 21 August 2019; Published: 22 August 2019 
Abstract: In mammal myocytes, endothelial cells and inner ear cells, ferlins are proteins involved in 
membrane processes such as fusion, recycling, endo- and exocytosis. They harbour several C2 
domains allowing their interaction with phospholipids. The expression of several Ferlin genes was 
described as altered in several tumoural tissues. Intriguingly, beyond a simple alteration, myoferlin, 
otoferlin and Fer1L4 expressions were negatively correlated with patient survival in some cancer 
types. Therefore, it can be assumed that membrane biology is of extreme importance for cell survival 
and signalling, making Ferlin proteins core machinery indispensable for cancer cell adaptation to 
hostile environments. The evidences suggest that myoferlin, when overexpressed, enhances cancer 
cell proliferation, migration and metabolism by affecting various aspects of membrane biology. 
Targeting myoferlin using pharmacological compounds, gene transfer technology, or interfering 
RNA is now considered as an emerging therapeutic strategy. 
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1. Introduction 
Ferlin is a family of proteins involved in vesicle fusions. To date, more than 760 articles in 
Pubmed refer to one of its members. Most of these publications are related to muscle biology, while 
less than 50 are directly related to cancer. However, the emerging idea of targeting plasma 
membranes [1] and the discovery of a significant correlation between Ferlin gene expression and 
cancer patient survival, brings attention to cancer. This review focused attention on the roles of these 
proteins, first in a healthy context, then in cancer. 
During the maturation of spermatids to motile spermatozoa in Caenorhabditis elegans worm, large 
vesicles called membranous organelles fuse with the spermatid plasma membrane. This step requires 
a functional FER-1 protein encoded by the fer-1 gene (fertilization defective-1) [2]. When FER-1 was 
identified and sequenced, no other known proteins had strong resemblance to it. Subsequently, 
homologs were found by sequence similarity in mammals, forming a family of similar proteins now 
called ferlins. In humans, a first C. elegans fer-1 homolog gene was discovered and the protein 
encoded by this gene was named dysferlin [3]. Shortly after, a second human FER-1-Like gene was 
identified. The product of the gene was named otoferlin [4]. The human EST database mining 
revealed a dysferlin paralog called myoferlin [5,6]. Three new members joined the ferlin gene family: 
FER1L4, a pseudogene; FER1L5; and FER1L6. The main features of ferlins are summarized in Table 
1. 
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Table 1. Short description of C. elegans and human ferlin genes and proteins. 
Protein Name 
(Uniprot Number) 
Gene Name Chromosome Mapping Main Protein Size 
Sperm vesicle fusion protein 
FER-1 (Q17388) 
fer-1  2034 AA (235 KDa) 
Dysferlin (O75923) Fer1-Like 1 
Fer1L1 
2p13.2 2080 AA (237 KDa) 
Otoferlin (Q9HC10) Fer1-Like 2 
Fer1L2 
2p23.3 1997 AA (227 KDa) 
Myoferlin (Q9NZM1) Fer1-Like 3 
Fer1L3 
10q23.33 2061 AA (230 KDa) 
FER1L4 (A9Z1Z3) Fer1-Like 4 
Fer1L4 
20q11.22 pseudogene 
FER1L5 (A0AVI2) Fer1-Like 5 
Fer1L5 
2q11.2 2057 AA (238 KDa) 
FER1L6 (Q2WGJ9) Fer1-Like 6 
Fer1L6 
8q24.13 1857 AA (209 KDa) 
The dysferlin mutations were involved in Limb-Girdle muscular dystrophy 2B (LGMD2B), a 
autosomal recessive degenerative myopathy, and in Miyoshi muscular dystrophy 1 (MMD1), a late-
onset muscular dystrophy [3,7]. The otoferlin mutations were described in the non-syndromic 
prelingual deafness (DFNB9) and in the auditory neuropathy autosomal recessive 1 (AUNB1) [4,8,9]. 
Nowadays, myoferlin and the 3 last members of the ferlin family are still not linked to human genetic 
diseases. However, myoferlin was proposed as a modifier protein for muscular dystrophy phenotype 
[5] and studies of myoferlin-null mice demonstrated impaired myoblast fusion and myofiber 
formation during muscle development and regeneration [10]. More recently, a truncated variant of 
myoferlin was associated with Limb-Girdle type muscular dystrophy and cardiomyopathy [11]. Here 
under, this review discusses that ferlins, mainly myoferlin, are involved in neoplastic diseases and 
are potential therapeutic targets. 
2. Genomic Organization of Ferlin Gene Family 
Ferlin genomic organization has not been extensively investigated. Nonetheless, valuable 
information was obtained from sequencing and subsequent gene annotation (www.ensembl.org). In 
C. elegans, fer-1 gene is approximately 8.6 kb in length and composed of 21 exons [2]. In humans, 
dysferlin gene (DYSF) is composed of 55 exons [12], and encodes 19 splice variant transcripts. 
Otoferlin gene (OTOF) contains 47 exons and encodes 7 splice variants. One of them is retaining an 
intronic sequence from other locus and is not coding for protein. An alternate splicing results in a 
neuronal-specific domain for otoferlin, regulated by the inclusion of exon 47 [8]. Myoferlin gene 
(MYOF), is composed of 54 exons and encodes for 9 splice variants. Four of them are not translated 
to protein and the shortest retains an intronic sequence. Myoferlin promoter includes several 
consensus-binding sites, such as for Myc, MEF2, CEBP, Sp1, AP1, and NFAT. The latter is able to bind 
endogenous NFATc1 and NFATc3 [13]. FER1L5 encodes 7 splice variants obtained by the 
arrangement of 53 exons. Five transcripts are known to encode proteins when the 2 shortest are 
retaining intronic sequences and do not encode protein. FER1L6 gene is composed of 41 exons and 
encodes a unique transcript. The main features of ferlin genes are summarized in Table 2. 
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Table 2. Short description of C. elegans and human ferlin genes and transcripts. 
Gene Name Gene Length Number of Exons Transcript Size Number of Variants 
Fer-1 8.6 kb 21 6.2 kb 3 
Fer1-Like 1 
Fer1L1 (DYSF) 
233 kb 55 0.5–6.7 kb 19 
Fer1-Like 2 
Fer1L2 (OTOF) 
121 kb 47 0.5–7.2 kb 7 
Fer1-Like 3 
Fer1L3 (MYOF) 
180 kb 54 0.4–6.7 kb 9 
Fer1-Like 4 
Fer1L4 
48 kb 43 0.2–5.9 kb 13 
Fer1-Like 5 
Fer1L5 
64 kb 53 3.5–6.5 kb 7 
Fer1-Like 6 
Fer1L6 
278 kb 41 6 kb 1 
3. Ferlin’s Structure and Localization 
Caenorrhabditis elegans FER-1 is a large protein rich in charged residues. Charged amino acids are 
distributed throughout the whole protein length such that no particularly acidic or basic domains are 
observed. The hydrophobicity plot described a 35 amino acid long hydrophobic region at the C-
terminal end [2]. To the authors’ knowledge, it has never been experimentally demonstrated. 
Similarity studies suggest that this region might be a transmembrane domain. FER-1 sequence 
analysis with Pfam protein families database [14] revealed the existence of 4 C2 domains and several 
other domains. 
Ferlins are proteins harboring multi-C2 domains. These structural domains are ~130 amino acid 
long independently folded modules found in several eukaryotic proteins. They were identified in 
classical Protein Kinase C (PKC) as the second conserved domain out of four. The typical C2 domain 
is composed of a beta-sandwich made of 8 beta-strands coordinating calcium ions, participating to 
their ability to bind phospholipids (for review [15]). However, some C2 domains have lost their 
capacity to bind calcium but still bind membranes [16]. A large variety of proteins containing C2 
domains have been identified, and most of them are involved in membrane biology, such as vesicular 
transport (synaptotagmin), GTPase regulation (Ras GTPase activating protein) or lipid modification 
(phospholipase C) (for review [17]). 
Human ferlin proteins harbour 5 to 7 C2 domains as described in the Pfam database (Figure 1A). 
According to this database, in humans, 342 proteins harbour C2 domains. However, the occurrence 
of multiple tandem C2 domains is uncommon. Only three vertebrate protein families contain more 
than two C2 domains: The multiple C2 domain and transmembrane region proteins (MCTP) [18], the 
E-Syt (extended synaptotagmins) [19], and the ferlins. The typical feature of a C2 domain is its ability 
to interact with two or three calcium ions. The prototype of this domain is the C2A contained in PKC 
that binds phospholipids in a calcium-dependent manner. Several other distinct C2 domain subtypes, 
e.g. those found in PI3K and in PTEN, do not have calcium binding abilities and instead specialize in 
protein-protein interactions [16,17]. In classical Ca2+-binding C2 domains, 5 aspartate residues are 
involved in the ion binding [20]. Clustal omega alignment of ferlin C2 domains with PKC and 
synaptotagmin I C2 domains revealed that the 5 Ca2+-binding aspartic acids were conserved or 
substituted by a glutamic acid in the C2E and C2F domains of all human paralogs (Figure 1B). The 
aspartic acid to glutamic acid substitution is considered as highly conservative and observed in some 
non-ferlin Ca2+-binding C2 domains [21]. Some ferlins showed more C2 domains with Ca2+-binding 
potential, e.g. dysferlin and myoferlin C2C and C2D, otoferlin C2D and fer1L6 C2D [22]. The 
phylogenic tree created by neighbour-joining of a Clustal omega alignment of C2 domain sequences 
shows that a C2 domain is more similar to others at a similar position in ortholog proteins than it is 
to the other C2 domains within the same protein [23]. A Clustal omega alignment reveals an 
evolutionary distribution of the ferlin proteins into two main subgroups (Figure 1C): The type 1 
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ferlins containing a DysF domain and the type-2 ferlins without the DysF domain [22]. This domain 
is present in yeast peroxisomal proteins where its established function is to regulate the peroxisome 
size and number [24]. In mammals, despite the fact that its solution structure was resolved [25] and 
that many pathogenic point mutations occur in this region [26,27], the function of this domain 
remains unknown. 
 
Figure 1. Structure and phylogenic relation of ferlin proteins. (A) Schematic structure of FER-1 human 
homologs as produced by Pfam protein families’ database. (B) Clustal omega multiple alignment of 
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ferlin C2 domains. Conserved Ca2+-binding site are highlighted in red (aspartic acid—D) or yellow 
(glutamic acid—E). (C) Cladogram of clustal omega alignment indicating type 1 ferlins in blue and 
type 2 ferlins in yellow. The branch length is indicated in grey. 
Immunodetection of a myoferlin-haemagglutinin fusion protein in non-permeabilised COS-7 
cells confirmed the presence of the C-terminal domain of the protein in the extracellular compartment 
[28], supporting the functionality of the putative trans-membrane region. The sublocalisation of 
ferlins was further studied, indicating robust membrane localisation for dysferlin, myoferlin and 
Fer1L6 while only low levels of otoferlin were at the plasma membrane and Fer1L5 was intracellular. 
Dysferlin and myoferlin were localised within the endo-lysosomal pathway accumulating in late 
endosomes and in recycling compartment. GFP-myoferlin fusion protein revealed that myoferlin was 
colocalized with lysosomal markers in NIH3T3 cells [29]. Otoferlin has been shown to move from the 
trans-Golgi network to the plasma membrane and inversely. Fer1L5 was cytosolic while Fer1L6 was 
detected in a specific sub-compartment of the trans-Golgi network compartment [30]. 
4. Ferlin’s Interactions with Phospholipids 
Ferlins are regarded as intrinsic membrane proteins through their putative transmembrane 
region. However, they can also interact with membranes by other domains. Experimentally, 
myoferlin C2A was the single C2 domain able to bind to phospholipid vesicles. A significant presence 
of the negatively charged phosphatidylserine (PS) was required for this interaction. Myoferlin C2A 
binding to PS-containing vesicles did not occur with calcium concentration similar to the one 
observed in the basal physiological condition (0.1 µM). Indeed, the half-maximal binding was 
observed at 1 µM [31], suggesting that the C2A domain is involved in specific processes inside the 
cell requiring Ca2+ release from intracellular stock, like in Ca2+-regulated exocytosis. When cells are 
stimulated by various means, including depolarization and ligand binding, the cytosolic Ca2+ 
concentration increases to the concentration up to 1 µM or more [32], similar to the one required by 
myoferlin C2A domain to bind lipids. It appears that dysferlin C2A domain has the same binding 
properties as myoferlin C2A domain. However, its half-maximal lipid binding was higher (4.5 µM) 
[31]. A recent publication confirmed that myoferlin and dysferlin C2A domains exhibit different Ca2+ 
affinities. However, they describe myoferlin C2A domain with a lower Ca2+ affinity than the dysferlin 
homolog C2 domain, and a marginal binding of myoferlin C2A domain to phospholipid mixture 
containing PS [33]. The binding of dysferlin C2A to PS was confirmed and extended to several 
phosphoinositide monophosphates in a Ca2+-dependent fashion. Therrien et al. observed that all 
remaining dysferlin C2 domains were able to bind to PS but independently of Ca2+ [34]. The laurdan 
fluorescence emission experiments suggest that dysferlin and myoferlin contribute to increase the 
lipid order in lipid vesicles. The magnitude of this observation was calcium-enhanced and C2 
domains within both N- and C-termini of ferlins influenced lipid packing. The experiments 
conducted with individual recombinant ferlin’s C2A-C domains demonstrated that all of them are 
able to increase lipid order [35]. 
The authors described in the first part of this review the conservation of the 5 Ca2+-binding 
aspartate residues in the C2D-F domains of otoferlin making them putative Ca2+-binding sites. In 
addition to its C2D-F domains, otoferlin is also able to bind Ca2+ via its C2B and C2C domains [36]. 
Despite the fact that C2A domain from otoferlin does not possess all five aspartate residues, its ability 
to bind Ca2+ is still under debate. Therrien and colleagues showed that otoferlin C2A domain can bind 
PS in a Ca2+-dependent fashion, suggesting an interaction with this ion [34]. This interaction was 
confirmed by a direct measure of otoferlin-binding to liposomes in the presence of Ca2+ (1mM). 
Moreover, C2A-C domains seem to bind lipids also under calcium free conditions [36]. At the 
opposite, a spectroscopy analysis indicates that otoferlin C2A domain is unable to coordinate Ca2+ 
ion [37]. 
Floatation assays were unable to confirm the interaction between otoferlin C2A and lipids. This 
may be due to the presence of a shorter membrane-interacting loop at the top of the domain [37]. As 
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for dysferlin and myoferlin, otoferlin increases lipid order in vesicles. However, its C2A does not 
participate to the phenomenon [35]. 
Ferlin proteins contain also a FerA domain recently described as a four-helix bundle fold with 
its own Ca2+-dependent phospholipid-binding activity [38]. 
5. Ferlin’s Main Functions in Non-Neoplastic Cells and Tissues 
5.1. In Mammal Muscle Cells 
Dysferlin and myoferlin have a specific temporal pattern of expression in an in vitro model of 
muscle development. Myoferlin was highly expressed in myoblasts that have elongated prior to 
fusion to syncytial myotubes. After fusion, myoferlin expression was decreased. The dysferlin 
expression increased concomitantly with the fusion and maturation of myotubes [31]. A proteomic 
analysis revealed the interacting partners of dysferlin during muscle differentiation [39]. It appeared 
that the number of partners decreases during the differentiation process, while the core-set of 
partners is large (115 proteins). Surprisingly, the dysferlin homolog myoferlin was consistently co-
immunoprecipitated with dysferlin. The gene ontology analysis of the core-set proteins indicates that 
the highest ranked clusters are related to vesicle trafficking. In the C2C12 myoblast model, 
immunoprecipitation experiments showed that myoferlin interacts with the Eps15 Homology 
Domain 2 (EHD2) apparently through a NPF (asparagine-proline-phenylalanine) motif in its C2B 
domain [40]. EHD2 has been implicated in endocytic recycling. It was inferred that the interaction 
between EHD2 and myoferlin might indirectly regulate disassembly or reorganization of the 
cytoskeleton that accompanies myoblast fusion. 
Dysferlin-null mice develop a slowly progressive muscular dystrophy with a loss of plasma 
membrane integrity. The presence of a stable and functional dystrophin–glycoprotein complex 
(DGC), involved in muscle injury-susceptibility when altered, suggests that dysferlin has a role in 
sarcolemma repair process. This was confirmed in dysferlin-null mice by a markedly delayed 
membrane resealing, even in the presence of Ca2+ [41]. Pharmacological experiments conducted in 
skeletal muscles demonstrated that dysferlin modulates smooth reticulum Ca2+ release and that in its 
absence injuries cause an increased ryanodine receptor (RyR1)-mediated Ca2+ leak from the smooth 
reticulum into the cytoplasm [42]. In the SJL/J mice model of dysferlinopathy, annexin-1 and -2 co-
precipitate with muscle dysferlin and co-localise at sarcolemma in an injury-dependent manner [43]. 
An immunofluorescence analysis of mitochondrial respiratory chain complexes in the muscles from 
the patients with dysferlinopathy revealed complex I- and complex IV-deficient myofibers [44]. This 
report is particularly interesting in light of the dysferlin_v1 alternate transcript discovered in skeletal 
muscle [45] and harboring a mitochondrial importation signal [39]. 
Intriguingly, at the site of membrane injury, only the C-terminal extremity of dysferlin was 
immunodetected. It was reported than dysferlin was cleaved by calpain [46], one of its interacting 
proteins [39]. The cleavage generate a C-terminal fragment called mini-dysferlinC72 bearing two 
cytoplasmic C2 domains anchored by a transmembrane domain [46]. Myoferlin expression is also up 
regulated in damaged myofibers and in surrounding mononuclear muscle and inflammatory cells 
[13]. As it was observed for dysferlin, myoferlin can be cleaved by calpain to produce a mini-
myoferlin module composed of the C2E and C2F domains [47]. 
Membrane repair requires the accumulation and fusion of vesicles with each other and with 
plasma membrane at the disruption point. A role for dysferlin and myoferlin in these processes is 
consistent with the presence of several C2 domains and with their homology with FER-1 having a 
role in vesicle fusion. Moreover, mini-dysferlin and mini-myoferlin bear structural resemblance to 
synaptotagmin, a well-known actor in synaptic vesicle fusion with the presynaptic membrane [48]. 
In mouse skeletal muscle, myoferlin was found at the nuclear and plasma membrane [5]. It is 
highly expressed in myoblasts before their fusion to myotubes [10,31] and found to be highly 
concentrated at the site of apposed myoblast and myotube membranes, and at site of contact between 
two myotubes [10]. Myoblast fusion requires a Ca2+ concentration increase to 1.4 µM [49], similar to 
the one reported for myoferlin C2A binding to phospholipids [31]. Myoferlin-null mice myoblasts 
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show impaired fusion in vitro, producing mice with smaller muscles and smaller myofibers in vivo 
[10]. All together, these observations support a role for myoferlin in the maturation of myotubes and 
the formation of large myotubes that arise from the fusion of myoblasts to multinucleated myotubes. 
Interestingly, myoferlin-null mice are unresponsive to IGF-1 for the myoblast fusion to the pre-
existing myofibers. Mechanistic experiments indicate a defect in IGF-1 internalization and a 
redirection of the IGF1R to the lysosomal degradation pathway instead of recycling. As expected, 
myoferlin-null myoblasts lacked the IGF1-induced increase in AKT and MAPK activity downstream 
to IGFR [50]. 
The defects in myoblast fusion and muscle repair observed in myoferlin-null mice are 
reminiscent of what was reported in muscle lacking nuclear factor of activated T-cells (NFAT). 
Demonbreun and colleagues suggested that in injured myofibers, the membrane damages induce an 
intracellular increase of Ca2+ concentration producing a calcineurin-dependent NFAT activation and 
subsequent translocation to the nucleus. The activated NFAT can therefore bind to its response 
element on the myoferlin promoter [13]. 
Using HeLa and HEK293T cell lines overexpressing ADAM-12, it was discovered that myoferlin 
was one of the ten most abundant interacting partners of ADAM-12 [51]. Though this was discovered 
in an artificial overexpressing model using cancer cells, it can be considered as pertinent in the context 
of muscle cell repair. Indeed, ADAM-12 is a marker of skeletal muscle regeneration interacting with 
the actin-binding protein α-actinin-2 in the context of myoblast fusion [52]. 
The differentiating myoblast C2C12 expressed Fer1L5 at the protein level with an expression 
pattern similar to dysferlin throughout myoblast differentiation. Fer1L5 shares with myoferlin a NPF 
motif in its C2B domain. As in myoferlin, this motif was described as interacting with EHD2, but also 
with EHD1 [53]. 
5.2. In mammal Inner Ear Cells 
In adult mouse cochlea, otoferlin gene expression is limited to inner hair cells (IHC) [4]. In these 
cells, the strongest immunostaining of otoferlin was associated with the basolateral region, where the 
afferent synaptic contacts are located, suggesting that otoferlin is a component of the IHC presynaptic 
machinery. Ultrastructural observations confirmed the association of otoferlin with the synaptic 
vesicles. It appears that otoferlin is not necessary for the synapse formation [54], but rather regulates 
the Ca2+-induced synaptic vesicle exocytosis [36]. 
At molecular level, otoferlin interacts with plasma membrane t-SNARE (soluble N-ethylmaleimide-
sensitive-factor attachment protein receptor) proteins (syntaxin 1 and SNAP-25) in a Ca2+-dependent 
manner [54]. Supporting this discovery, both t-SNARE proteins are known to interact with 
synaptotagmin I, a C2 domain harbouring protein, in the context of the classical synaptic vesicles 
docking [55,56]. It was reported that otoferlin relies on C2F domain for its Ca2+-dependent interaction 
with t-SNARE [57–59]. However, others suggest a Ca2+-dependent interaction through the C2C, C2D, 
C2E and C2F domains and a Ca2+-independent interaction via the C2A and C2B domains. The 
SNARE-mediated membrane fusion was reconstituted with proteoliposomes. This assay indicates 
that in presence of Ca2+, otoferlin accelerates the fusion process [36], suggesting that otoferlin operates 
as a calcium-sensor for SNARE-mediated membrane fusion. 
5.3. In Mammal Endothelial Cells 
Bernatchez and colleagues reported that dysferlin and myoferlin are abundant in caveolae-
enriched membrane microdomains/lipid rafts (CEM/LR) isolated from human endothelial cells and 
are highly expressed in mouse blood vessels [28,60]. As observed for dysferlin in muscle cells, 
myoferlin regulates the endothelial cell membrane resealing after physical damage. In endothelial 
cells, myoferlin silencing reduced or abolished the ERK-1/2, JNK or PLCγ phosphorylation by VEGF, 
resulting from a loss of VEGFR-2 stabilization at the membrane. Indeed, myoferlin silencing caused 
an increase in VEGFR2 polyubiquitination, which leads to its degradation [28]. In contrast to what 
was observed in myoferlin-silenced endothelial cells, dysferlin gene silencing decrease neither 
VEGFR2 expression nor its downstream signalling. However, dysferlin-siRNA treated endothelial 
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cells showed a near-complete inhibition of proliferation when they were sub-confluent. The 
proliferation decrease seems to be due to an impaired attachment rather than to cell death, as 
supported by adhesion assays and PECAM-1 poly-ubiquitination that leads to its degradation. Co-
immunoprecipitation and co-localisation experiments support the formation of a molecular complex 
between dysferlin and PECAM-1. This PECAM-1 degradation leads, in dysferlin-null mice, to a 
blunted VEGF-induced angiogenesis [60]. Another angiogenic tyrosine kinase receptor Tie-2 
(tyrosine kinase with Ig and epidermal growth factor homology domains-2) is significantly less 
expressed at the plasma membrane when myoferlin is silenced in endothelial cells [61]. In this case, 
it appears that proteasomal degradation plays a minor role in the down regulation of the receptor. 
Strikingly, G-protein coupled receptors (GCPR) were unaffected by the decrease of myoferlin 
expression, suggesting a selective effect on receptor tyrosine kinases (RTK). 
It was also reported that in endothelial cells, myoferlin is required for an efficient clathrin and 
caveolae/raft-dependent endocytosis, is co-localized with Dynamin-2 protein [62] and that the FASL-
induced lysosome fusion to plasma membrane is mediated by dysferlin C2A domain [63]. 
5.4. Other Mammal’s Cells 
Dysferlin and myoferlin are expressed in both basal and ciliated airway epithelial cells from 
healthy human lungs [64]. In the airway epithelial cell line (16HBE), dysferlin and myoferlin were 
immuno-detected at the plasma membrane, Golgi membrane and in cytoplasm but not in the nuclei. 
The silencing of myoferlin in these cells induces the loss of zonula occludens (ZO)-1, inducing 
apoptosis [64]. 
Myoferlin was also detected in exosomes from human eye trabecular meshwork cells [65] and 
in phagocytes where it participates to the fusion between lysosomes and the plasma membrane, thus 
promoting the release of lysosomal contents [29]. 
The Fer1L5 gene expression was largely restricted to the pancreas, where it was alternatively 
spliced by removing exon 51 [30]. 
6. Ferlins in Cancer, Potential Targets to Kill Cancer 
It is clear from the data above that ferlins are consistently involved in membrane processes 
requiring membrane fusion, including endocytosis, exocytosis, membrane repair, recycling and 
remodelling. Membrane processes are of extreme importance for cell survival and signalling, making 
them core machinery for cancer cell adaptation to hostile environments. 
Considering that ferlins have been only scarcely investigated in cancer, the authors next sought 
to mine publicly available databases and gain information regarding ferlin’s expression or mutation 
in tumors. Using the FireBrowse gene expression viewer (firebrowse.org), The Cancer Genome Atlas 
(TCGA) RNAseq data of all ferlin’s genes in neoplastic tissues were investigated in order to obtain a 
differential expression in comparison to their normal counterparts. It appears that all ferlin genes are 
modulated in several cancer types. Myoferlin and fer1l4 genes are more frequently up regulated than 
down regulated, while dysferlin, fer1l5, and fer1l6 are more frequently down regulated (Figure 2). 
Experimentally, a myoferlin gene was discovered as highly expressed in several tumour tissues 
including the pancreas [66,67], breast [68], kidneys [68], and head and neck squamous cell carcinoma 
(HNSCC) [69]. This expression was confirmed at a protein level in tumour tissue and/or cell lines 
from the pancreas [70–73], breast [74,75], lungs [75], melanoma [75], hepatocellular carcinoma [76], 
HNSCC [77], clear cell renal carcinoma [78,79], and endometroid carcinoma [80]. Myoferlin was also 
detected at a protein level in microvesicles/exosomes derived from several cancer cells including the 
bladder [81], colon [82–85], ovary [86], prostate [87], breast and pancreas, where it plays a role in 
vesicle fusion with the recipient endothelial cells [88]. 
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Figure 2. Ferlin gene expression in several cancers (red) and their normal counterparts (blue). Cancer 
tissues from adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), breast invasive 
carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), 
cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), colorectal adenocarcinoma 
(COADREAD), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), esophageal carcinoma 
(ESCA), glioblastoma multiforme (GBM), glioma (GBMLGG), head and neck squamous cell 
carcinoma (HNSC), kidney chromophobe (KICH), pan-kidney cohort (KIPAN), kidney renal clear cell 
carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), 
brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma 
(LUAD), lung squamous cell carcinoma (LUBC), mesothelioma (MESO), ovarian serous 
cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), pheochromocytoma and 
paraganglioma (PCPG), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), sarcoma 
(SARC), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), stomach and 
esophageal carcinoma (STES), testicular germ cell tumours (TGCT), thyroid carcinoma (THCA), 
thymoma (THYM), uterine corpus endometrial carcinoma (UCEC), uterine carcinosarcoma (UCS), 
uveal melanoma (UVM). 
This review then explored the mutations occurring in ferlin genes in tumours using Tumorportal 
(http://www.tumorportal.org) [89]. Several mutations were reported in ferlin genes in a few cancer 
types. However, none of them were considered as significant. Survival was also analysed (Table 3) 
using a pan-cancer method available online (OncoLnc–http://www.oncolnc.org) and combining 
mRNAs, miRNAs, and lncRNAs expression [90]. Noticeably, otoferlin expression was strongly 
significantly correlated with survival in renal clear cell carcinoma (KIRC–p < 10–5); myoferlin 
expression was strongly significantly correlated with survival in brain lower grade glioma (LGG–p < 
10–4) and pancreatic adenocarcinoma (PAAD–p < 10–4), and Fer1l4 expression was strongly 
significantly correlated with survival in bladder urothelial carcinoma (BLCA–p < 10–5) and kidney 
renal clear cell carcinoma (KIRC–p < 10–5). The 5 more significant correlations between ferlin’s 
expression and the overall survival were represented as Kaplan-Meier curves with their associated 
log-rank p-value (Figure 3).  
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Table 3. Survival analysis by a Cox regression. 
Positive Association Negative Association 
Cohort Cox Coefficient p-Value Cohort Cox Coefficient P-Value 
DYSF EXPRESSION 
CESC 0.266 4.20e–02 SARC –0.277 1.00e–02 
STAD 0.171 4.80e–02 KIRC –0.220 1.00e–02 
OTOF EXPRESSION 
KIRC 0.377 1.50e–06 BLCA –0.275 4.50e–04 
KIRP 0.413 4.90e–03 SKCM –0.169 1.40e–02 
MYOF EXPRESSION 
LGG 0.441 1.40e–05 SKCM –0.163 1.90e–02 
PAAD 0.561 1.70e–05    
LAML 0.215 4.70e–02    
FER1L4 EXPRESSION 
KIRC 0.356 5.20e–06 BLCA -0.383 2.90e–06 
KIRP 0.492 1.10e–03 SKCM –0.225 1.10e–03 
LGG 0.244 4.00e–03    
FER1L5 EXPRESSION 
LUAD –0.199 1.30e–02    
FER1L6 EXPRESSION 
KIRC –0.160 4.80e–02    
READ –0.401 4.90e–02    
Ferlin gene expression from cohorts with cancer was submitted to a survival analysis with a Cox 
regression. The red rows indicate a negative Cox coefficient, the green rows indicate positive Cox 
coefficient. The bold p-values were considered as highly significant (p < 10–4). Bladder urothelial 
carcinoma (BLCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), 
kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid 
leukemia (LAML), brain lower grade glioma (LGG), lung adenocarcinoma (LUAD), pancreatic 
adenocarcinoma (PAAD), rectum adenocarcinoma (READ), sarcoma (SARC), skin cutaneous 
melanoma (SKCM), stomach adenocarcinoma (STAD). 
Interestingly, a recent publication points out specific single nucleotide polymorphisms in 
dysferlin genes as significantly associated with pancreas cancer patient survival [91]. Mining the 
TCGA database, a high Fer1L4 expression was reported as a predictor of a poor prognosis in glioma 
[92,93] and as an oncogenic driver in several human cancers [94]. However, several other publications 
pointed it out as a predictor of good prognosis in osteosarcoma [95], gastric cancer [96], endometrial 
carcinoma [97]. 
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Figure 3. Kaplan-Meier survival curves of patient cohorts with different cancer types. Ferlin gene 
expression was segregated in low (blue) and high (red) expression according to median in kidney 
renal clear cell carcinoma (KIRC), brain lower grade glioma (LGG), bladder urothelial carcinoma 
(BLCA), and pancreatic adenocarcinoma (PAAD). 
6.1. Breast Cancer and Melanoma 
A mathematical model was proposed to examine the role of myoferlin in cancer cell invasion. 
This model confirms the experimental observation of decreased invasion of the myoferlin-null breast 
MDA-MB-231 cell line, and predicts that the pro-invasion effect of myoferlin may be in large partly 
mediated by MMPs [98]. The model was further validated in vitro suggesting a mesenchymal to 
epithelial transition (MET) when myoferlin was knockdown [99,100]. Using the same cell model, 
Blackstone and colleagues showed that myoferlin depletion increased cell adhesion to PET substrate 
by enhancing focal adhesion kinase (FAK) and its associated protein paxillin (PAX) phosphorylation 
[101]. Interestingly, myoferlin was reported as regulating the cell migration through a TGF-β1 
autocrine loop [102]. Recently, related results were reported in melanoma [103]. Myoferlin expression 
was first correlated with vasculogenic mimicry (VM) in patients, then its in vitro depletion in A375 
cell line impaired VM, migration, and invasion by decreasing MMP-2 production. 
Several evidences, obtained from normal endothelial cells, indicate that myoferlin is involved in 
RTKs recycling (see above). Our group showed that MDA-MB-231 and -468 cells depleted for 
myoferlin were unable to migrate and to undergo EMT upon EGF stimulation. The authors 
discovered that myoferlin depletion altered the EGFR fate after ligand binding, most probably by 
inhibiting the non-clathrin mediated endocytosis [104]. Unexpectedly, myoferlin seemed to be 
physically associated with lysosomal fraction in MCF-7 cells [105], supporting its involvement in the 
membrane receptor recycling. 
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The co-localisation of myoferlin with caveolin-1 [104], the main component of caveolae 
considered as a metabolic hub [106] prompted our group to investigate the implication of myoferlin 
in energy metabolism. In this context, the authors showed in triple-negative breast cancer cells that 
myoferlin-silencing produces an accumulation of monounsaturated fatty acids (C16:1). Its depletion 
further decreased oxygen consumption switching the cell metabolism toward glycolysis [107]. This 
was the first report of the role of myoferlin in mitochondrial function and cell metabolism. A recent 
report describing the link between dysferlin mutations and mitochondrial respiratory complexes in 
muscular dysferlinopathy emerged (see above) [44]. It is also intriguing that dysferlin_v1 alternate 
transcript discovered in skeletal muscle [45] harbours a mitochondrial importation signal [39]. 
Several breast cancer cell lines and tissues showed a calpain-independent myoferlin cleavage, 
regardless of cell injuries and subsequent Ca2+ influx [108]. The resulting cleaved myoferlin increases 
ERK phosphorylation in an overexpressing HEK293 system. It would be of interest to further study 
the link between mini-myoferlin and KRAS mutated cancers as ERK is a mid-pathway signalling 
protein in this context. 
6.2. Pancreas and Colon Cancers 
In pancreas adenocarcinoma (PAAD), myoferlin is overexpressed in high grade PAAD in 
comparison to low grade [73]. The patients with high myoferlin PAAD had a significantly worse 
prognosis than those with low myoferlin PAAD, with myoferlin appearing as an independent 
prognosis factor. The experiments undertaken with pancreatic cell lines and siRNA-mediated 
silencing demonstrated that myoferlin requested to maintain a high proliferation rate. The authors 
reported that myoferlin is a key element in VEGF exocytosis by PAAD cell lines, correlating with 
microvessel density in PAAD tissue [109]. Recently, it was demonstrated that myoferlin is critical to 
maintain mitochondrial structure and oxidative phosphorylation [110]. This discovery was extended 
to colon cancer where myoferlin seemed also to protect cells from p53-driven apoptosis [111]. The 
concept claiming that metastatic dissemination relies on oxidative phosphorylation is broadly 
accepted [112,113]. Based on these reports, the authors discovered that myoferlin was overexpressed 
in PAAD cells with a high metastatic potential, where it controls mitochondrial respiration [114]. 
Recently, FER1L4 methylated DNA marker in pancreatic juice has been strongly associated with 
pancreatic ductal adenocarcinoma suggesting its use as a biomarker for early detection [115]. 
6.3. Lung Cancer 
In mice bearing solid LLC lung tumours, the intratumoral injection of myoferlin siRNA mixed 
with a lipidic vector reduced the tumour volume by 73%. The observed reduction was neither the 
consequence of a difference in blood vessel density nor of VEGF secretion. However, a significant 
reduction of the proportion of the Ki67-positive cells indicated a decrease in cell proliferation [75]. 
Myoferlin was reported as expressed in human non-small cell lung cancer tissues where it was 
correlated with VEGFR2, thyroid transcription factor (TTF)-1 and transformation-related protein 
(p63), especially in the low stage tumours [116]. 
Recently, it was suggested that long non-coding RNA Fer1L4 negatively controlled proliferation 
and migration of lung cancer cells, probably through the PI3K/AKT pathway [117]. The same 
observation was made in osteosarcoma cells [118], esophageal squamous cell carcinoma [119], and 
hepatocellular carcinoma [120]. 
6.4. Liver Cancer 
In the hepatocellular carcinoma (HCC) cell line, the silencing of the transcriptional coactivator 
of the serum response factor (SRF), Megakaryoblastic Leukemia 1/2 (MKL1/2), induced a reduction 
of myoferlin gene expression. It was shown by chromatin immunoprecipitation that MKL1/2 binds 
effectively to the myoferlin promoter [76]. As in other cancer types, HCC required myoferlin to 
proliferate and perform invasion or anchorage-independent cell growth. Its depletion enhanced 
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EGFR phosphorylation, in agreement with the concept of myoferlin being a regulator of RTK 
recycling. 
6.5. Head and Neck Cancer 
A myoferlin expression pattern was investigated in oropharyngeal squamous carcinoma 
(OPSCC). It was reported that myoferlin was overexpressed in 50% of the cases and significantly 
associated with worse survival. Moreover, HPV-negative patients had significantly higher 
expressions of myoferlin. A subgroup survival analysis indicates the interaction between these two 
parameters as HPV-negative has the worst prognosis when myoferlin is highly expressed. Nuclear 
myoferlin expression appeared to be highly predictive of the clinical outcome and associated with 
IL-6 and nanog overexpression [77]. Upon HNSCC cell line stimulation with IL-6, myoferlin 
dissociates from EHD2 and binds activated STAT3 to drive it in the nucleus. The observation was 
extended to breast cancer cell lines [69]. 
6.6. Gastric Cancer 
Recently, a profiling study reported that FER1L4 was a long non-coding RNA (lncRNA) strongly 
downregulated in gastric cancer tissue [96], in plasma from gastric cancer patients [121] and in human 
gastric cancer cell lines [122]. In gastric cancer tissues, FER1L4 lncRNA was associated with the 
tumour diameter, differentiation state, tumour classification, invasion, metastasis, TNM stage and 
serum CA72-4. Interestingly, the abundance of this lncRNA decreases in plasma shortly after surgery 
[121]. The same team reported that the FER1L4 lncRNA is a target of miR-106a-5p [122,123]. The cell 
depletion in FER1L4 lncRNA resulted in an increase in miR-106a-5p and in a decrease of its 
endogenous target PTEN, suggesting a competing endogenous RNA (ceRNA) [124] role for FER1L4 
lncRNA [122]. The control of miR-106a-5p by FER1L4 lncRNA was extended to colon cancer [125] 
and HCC [126], while it was described over miR-18a-5p in osteosarcoma [127]. 
6.7. Gynecological Cancers 
Lnc Fer1L4 was briefly investigated in ovarian cancer where it was described as downregulated 
in cancer cells in comparison to normal ovarian epithelial cells [128]. Interestingly, the Fer1L4 
expression correlates negatively with the paclitaxel resistance and its re-expression restore the 
paclitaxel sensitivity through the inhibition of a MAPK signalling pathway. 
7. Conclusion 
This review clearly shows that all ferlin proteins are membrane-based molecular actors sharing 
structural similarities. Far beyond their well-described involvement in physiological membrane 
fusion, several correlations apparently link ferlins, and most particularly myoferlin, to cancer 
prognosis. However, further investigations are still needed to discover the direct link between 
myoferlin and cancer biology. Encouragingly, there are many indications that myoferlin depletion 
interferes with growth factor exocytosis, surface receptor fate determination, exosome composition, 
and metabolism, indicating the future research axes. 
Self-sufficiency in growth factor signalling is a hallmark of cancer cells. Cancer cells overproduce 
the growth factor to stimulate unregulated proliferation in an autocrine, juxtacrine or paracrine 
fashions. In this context, myoferlin could be considered as a cancer growth promoter as it helps the 
exocytosis of the growth factors, at least VEGF. In normal cells, myoferlin was described as involved 
in receptor tyrosine kinase (EGFR and VEGFR) recycling or expression, allowing as such, the cell 
response to the growth factors. Knowing that some cancer cells exhibit mutations in tyrosine kinase 
receptors, which lead to a constitutive receptor activation triggering the downstream pathways, it 
can be speculated that myoferlin depletion could impede cell proliferation in these cases. This role 
was indeed described in breast cancer cells [104]. 
Exosomes are small extracellular vesicles released on exocytosis of multivesicular bodies filled 
with intraluminal vesicles. They represent an important role in intercellular communication, serving 
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as carrier for the transfer of miRNA and proteins between cells. The exosomes are increasingly 
described as cancer biomarkers [129] and involved in the preparation of the tumour 
microenvironment [130]. Interestingly, myoferlin was demonstrated to be present in exosomes 
isolated from several cancer cell types. However, the biological significance of this localization has 
still to be investigated. 
Metabolism recently integrated the hallmarks of cancer [131], and mitochondria were recognised 
as key players in cancer metabolism [132]. The indications that myoferlin is necessary for optimal 
mitochondrial function is a promising avenue in the search for an innovative therapy. 
Myoferlin, being overexpressed in several cancer types, offers very promising advantages for 
cancer diagnosis and targeting. Targeting myoferlin at the expression or functional levels remains, 
however, the next challenge. Interestingly, recent studies identified new small compounds 
interacting with the myoferlin C2D domain and demonstrating promising anti-tumoral/metastasis 
properties in breast and pancreas cancer [133,134]. 
Gene transfer strategies have undergone profound development in recent years and this is 
particularly applicable for recessive disorders. The adeno-associated virus (AAV) is a non-pathogenic 
vector used in a treatment strategy aiming at delivering full-length dysferlin or shorter variants to 
skeletal muscle in dysferlin-null mice. Several well documented reports demonstrate an 
improvement in the outcome measures after dysferlin gene therapy [135–138]. Similar AAV vectors 
were used as a gene delivery system in cancer [139,140], allowing the dream of myoferlin negative-
dominant delivery to cancer cells. Moreover, the sleeping beauty transposon system [141] may 
overcome some of the limitations associated with viral gene transfer vectors and transient non-viral 
gene delivery approaches that are being used in the majority of ongoing clinical trials. 
8. Statistical methods 
The multivariate Cox regressions (Table 3) were performed with the coxph function from the R 
survival library. For each cancer and data type, OncoLnc attempted to construct a model with gene 
expression, sex, age, and grade or histology as multivariates [90]. The clinical information was 
obtained from TCGA and only patients who contained all the necessary clinical information were 
included in the analysis. The patients were split into low and high expressing according to the median 
gene expression. 
Funding: This research was funded by “Fonds Léon Fredericq” and by the “Patrimoine de l’Université de Liège”. 
Acknowledgments: The results published here are in whole or part based upon data generated by the TCGA 
Research Network: http://cancergenome.nih.gov/. AB is a Research Director at the National Fund for Scientific 
Research (FNRS), Belgium. SA is supported by a FNRS FRIA grant. AT acknowledges LabEx MAbImprove for 
financial support. 
Conflicts of Interest: The authors declare no conflicts of interest. The funders had no role in the design of the 
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to 
publish the results. 
References 
1. Bernardes, N.; Fialho, A.M. Perturbing the Dynamics and Organization of Cell Membrane Components: A 
New Paradigm for Cancer-Targeted Therapies. Int. J. Mol. Sci. 2018, 19, 3871. 
2. Achanzar, W.E.; Ward, S. A nematode gene required for sperm vesicle fusion. J. Cell Sci. 1997, 110, 1073–
1081. 
3. Bashir, R.; Britton, S.; Strachan, T.; Keers, S.; Vafiadaki, E.; Lako, M.; Richard, I.; Marchand, S.; Bourg, N.; 
Argov, Z.; et al. A gene related to caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-
girdle muscular dystrophy type 2B. Nat. Genet. 1998, 20, 37–42. 
4. Yasunaga, S.; Grati, M.; Cohen-Salmon, M.; El-Amraoui, A.; Mustapha, M.; Salem, N.; El-Zir, E.; Loiselet, 
J.; Petit, C. A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyndromic 
form of deafness. Nat. Genet. 1999, 21, 363–369. 
5. Davis, D.B.; Delmonte, A.J.; Ly, C.T.; McNally, E.M. Myoferlin, a candidate gene and potential modifier of 
muscular dystrophy. Hum. Mol. Genet. 2000, 9, 217–226. 
Cells 2019, 8, 954 15 of 21 
 
6. Britton, S.; Freeman, T.; Vafiadaki, E.; Keers, S.; Harrison, R.; Bushby, K.; Bashir, R. The third human FER-
1-like protein is highly similar to dysferlin. Genomics 2000, 68, 313–321. 
7. Liu, J.; Aoki, M.; Illa, I.; Wu, C.; Fardeau, M.; Angelini, C.; Serrano, C.; Urtizberea, J.A.; Hentati, F.; Hamida, 
M.B.; et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle 
muscular dystrophy. Nat. Genet. 1998, 20, 31–36. 
8. Choi, B.Y.; Ahmed, Z.M.; Riazuddin, S.; Bhinder, M.A.; Shahzad, M.; Husnain, T.; Griffith, A.J.; Friedman, 
T.B. Identities and frequencies of mutations of the otoferlin gene (OTOF) causing DFNB9 deafness in 
Pakistan. Clin. Genet. 2009, 75, 237–243. 
9. Tekin, M.; Akcayoz, D.; Incesulu, A. A novel missense mutation in a C2 domain of OTOF results in 
autosomal recessive auditory neuropathy. Am. J. Med. Genet. A 2005, 138, 6–10. 
10. Doherty, K.R.; Cave, A.; Davis, D.B.; Delmonte, A.J.; Posey, A.; Earley, J.U.; Hadhazy, M.; McNally, E.M. 
Normal myoblast fusion requires myoferlin. Development 2005, 132, 5565–5575. 
11. Kiselev, A.; Vaz, R.; Knyazeva, A.; Sergushichev, A.; Dmitrieva, R.; Khudiakov, A.; Jorholt, J.; Smolina, N.; 
Sukhareva, K.; Fomicheva, Y.; et al. Truncating variant in myof gene is associated with limb-girdle type 
muscular dystrophy and cardiomyopathy. Front. Genet. 2019, 10, 608. 
12. Aoki, M.; Liu, J.; Richard, I.; Bashir, R.; Britton, S.; Keers, S.M.; Oeltjen, J.; Brown, H.E.; Marchand, S.; Bourg, 
N.; et al. Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. Neurology 
2001, 57, 271–278. 
13. Demonbreun, A.R.; Lapidos, K.A.; Heretis, K.; Levin, S.; Dale, R.; Pytel, P.; Svensson, E.C.; McNally, E.M. 
Myoferlin regulation by NFAT in muscle injury, regeneration and repair. J. Cell Sci. 2010, 123, 2413–2422. 
14. Finn, R.D.; Coggill, P.; Eberhardt, R.Y.; Eddy, S.R.; Mistry, J.; Mitchell, A.L.; Potter, S.C.; Punta, M.; Qureshi, 
M.; Sangrador-Vegas, A.; et al. The Pfam protein families database: Towards a more sustainable future. 
Nucleic Acids Res. 2016, 44, D279–D285. 
15. Corbalan-Garcia, S.; Gómez-Fernández, J.C. Signaling through C2 domains: More than one lipid target. 
Biochim. Biophys. Acta 2014, 1838, 1536–1547. 
16. Zhang, D.; Aravind, L. Identification of novel families and classification of the C2 domain superfamily 
elucidate the origin and evolution of membrane targeting activities in eukaryotes. Gene 2010, 469, 18–30. 
17. Nalefski, E.A.; Falke, J.J. The C2 domain calcium-binding motif: Structural and functional diversity. Protein 
Sci. 1996, 5, 2375–2390. 
18. Shin, O.-H.; Han, W.; Wang, Y.; Südhof, T.C. Evolutionarily conserved multiple C2 domain proteins with 
two transmembrane regions (MCTPs) and unusual Ca2+ binding properties. J. Biol. Chem. 2005, 280, 1641–
1651. 
19. Min, S.-W.; Chang, W.-P.; Südhof, T.C. E-Syts, a family of membranous Ca2+-sensor proteins with multiple 
C2 domains. Proc. Natl. Acad. Sci. USA 2007, 104, 3823–3828. 
20. Rizo, J.; Sudhof, T.C. C2-domains, structure and function of a universal Ca2+-binding domain. J. Biol. Chem. 
1998, 273, 15879–15882. 
21. von Poser, C.; Ichtchenko, K.; Shao, X.; Rizo, J.; Sudhof, T.C. The evolutionary pressure to inactivate. A 
subclass of synaptotagmins with an amino acid substitution that abolishes Ca2+ binding. J. Biol. Chem. 1997, 
272, 14314–14319. 
22. Lek, A.; Lek, M.; North, K.N.; Cooper, S.T. Phylogenetic analysis of ferlin genes reveals ancient eukaryotic 
origins. BMC Evol. Biol. 2010, 10, 231. 
23. Washington, N.L.; Ward, S. FER-1 regulates Ca2+ -mediated membrane fusion during C. elegans 
spermatogenesis. J. Cell Sci. 2006, 119, 2552–2562. 
24. Yan, M.; Rachubinski, D.A.; Joshi, S.; Rachubinski, R.A.; Subramani, S. Dysferlin domain-containing 
proteins, Pex30p and Pex31p, localized to two compartments, control the number and size of oleate-
induced peroxisomes in Pichia pastoris. Mol. Biol. Cell. 2008, 19, 885–898. 
25. Patel, P.; Harris, R.; Geddes, S.M.; Strehle, E.-M.; Watson, J.D.; Bashir, R.; Bushby, K.; Driscoll, P.C.; Keep, 
N.H. Solution Structure of the Inner DysF Domain of Myoferlin and Implications for Limb Girdle Muscular 
Dystrophy Type 2B. J. Mol. Biol. 2008, 379, 981–990. 
26. Fuson, K.; Rice, A.; Mahling, R.; Snow, A.; Nayak, K.; Shanbhogue, P.; Meyer, A.G.; Redpath, G.M.I.; 
Hinderliter, A.; Cooper, S.T.; et al. Alternate splicing of dysferlin C2A confers Ca2+-dependent and Ca2+-
independent binding for membrane repair. Structure 2014, 22, 104–115. 
Cells 2019, 8, 954 16 of 21 
 
27. Aartsma-Rus, A.; Van Deutekom, J.C.T.; Fokkema, I.F.; Van Ommen, G.-J. B.; Den Dunnen, J.T. Entries in 
the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and 
paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006, 34, 135–144. 
28. Bernatchez, P.N.; Acevedo, L.; Fernandez-Hernando, C.; Murata, T.; Chalouni, C.; Kim, J.; Erdjument-
Bromage, H.; Shah, V.; Gratton, J.-P.; McNally, E.M.; et al. Myoferlin regulates vascular endothelial growth 
factor receptor-2 stability and function. J. Biol. Chem. 2007, 282, 30745–30753. 
29. Miyatake, Y.; Yamano, T.; Hanayama, R. Myoferlin-Mediated Lysosomal Exocytosis Regulates Cytotoxicity 
by Phagocytes. J. Immunol. 2018, 201, 3051–3057. 
30. Redpath, G.M.I.; Sophocleous, R.A.; Turnbull, L.; Whitchurch, C.B.; Cooper, S.T. Ferlins Show Tissue-
Specific Expression and Segregate as Plasma Membrane/Late Endosomal or Trans-Golgi/Recycling Ferlins. 
Traffic 2016, 17, 245–266. 
31. Davis, D.B.; Doherty, K.R.; Delmonte, A.J.; McNally, E.M. Calcium-sensitive phospholipid binding 
properties of normal and mutant ferlin C2 domains. J. Biol. Chem. 2002, 277, 22883–22888. 
32. Bootman, M.D.; Rietdorf, K.; Hardy, H.; Dautova, Y.; Corps, E.; Pierro, C.; Stapleton, E.; Kang, E.; Proudfoot, 
D. Calcium Signalling and Regulation of Cell Function. In eLS; John Wiley & Sons, Ltd.: Chichester, UK, 
2012; pp. 1–14. 
33. Harsini, F.M.; Bui, A.A.; Rice, A.M.; Chebrolu, S.; Fuson, K.L.; Turtoi, A.; Bradberry, M.; Chapman, E.R.; 
Sutton, R.B. Structural Basis for the Distinct Membrane Binding Activity of the Homologous C2A Domains 
of Myoferlin and Dysferlin. J. Mol. Biol. 2019, 431, 2112–2126. 
34. Therrien, C.; Fulvio, S.D.; Pickles, S.; Sinnreich, M. Characterization of lipid binding specificities of 
dysferlin C2 domains reveals novel interactions with phosphoinositides. Biochemistry 2009, 48, 2377–2384. 
35. Marty, N.J.; Holman, C.L.; Abdullah, N.; Johnson, C.P. The C2 domains of otoferlin, dysferlin, and 
myoferlin alter the packing of lipid bilayers. Biochemistry 2013, 52, 5585–5592. 
36. Johnson, C.P.; Chapman, E.R. Otoferlin is a calcium sensor that directly regulates SNARE-mediated 
membrane fusion. J. Cell Biol. 2010, 191, 187–197. 
37. Helfmann, S.; Neumann, P.; Tittmann, K.; Moser, T.; Ficner, R.; Reisinger, E. The Crystal Structure of the 
C2A Domain of Otoferlin Reveals an Unconventional Top Loop Region. J. Mol. Biol. 2011, 406, 479–490. 
38. Harsini, F.M.; Chebrolu, S.; Fuson, K.L.; White, M.A.; Rice, A.M.; Sutton, R.B. FerA is a Membrane-
Associating Four-Helix Bundle Domain in the Ferlin Family of Membrane-Fusion Proteins. Sci. Rep. 2018, 
8, 10949. 
39. de Morrée, A.; Hensbergen, P.J.; van Haagen, H.H.; Dragan, I.; Deelder, A.M.; AC’t Hoen, P.; Frants, R.R.; 
van der Maarel, S.M. Proteomic analysis of the dysferlin protein complex unveils its importance for 
sarcolemmal maintenance and integrity. PLoS ONE 2010, 5, e13854. 
40. Doherty, K.R.; Demonbreun, A.R.; Wallace, G.Q.; Cave, A.; Posey, A.D.; Heretis, K.; Pytel, P.; McNally, E.M. 
The endocytic recycling protein EHD2 interacts with myoferlin to regulate myoblast fusion. J. Biol. Chem. 
2008, 283, 20252–20260. 
41. Bansal, D.; Miyake, K.; Vogel, S.S.; Groh, S.; Chen, C.-C.; Williamson, R.; McNeil, P.L.; Campbell, K.P. 
Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003, 423, 168–172. 
42. Lukyanenko, V.; Muriel, J.M.; Bloch, R.J. Coupling of excitation to Ca (2+) release is modulated by dysferlin. 
J. Physiol. 2017, 595, 5191–5207. 
43. Lennon, N.J.; Kho, A.; Bacskai, B.J.; Perlmutter, S.L.; Hyman, B.T.; Brown, R.H. Dysferlin Interacts with 
Annexins A1 and A2 and Mediates Sarcolemmal Wound-healing. J. Biol. Chem. 2003, 278, 50466–50473. 
44. Vincent, A.E.; Rosa, H.S.; Alston, C.L.; Grady, J.P.; Rygiel, K.A.; Rocha, M.C.; Barresi, R.; Taylor, R.W.; 
Turnbull, D.M. Dysferlin mutations and mitochondrial dysfunction. Neuromuscul. Disord. 2016, 26, 782–788. 
45. Pramono, Z.A.D.; Lai, P.S.; Tan, C.L.; Takeda, S.; Yee, W.C. Identification and characterization of a novel 
human dysferlin transcript: Dysferlin_v1. Hum. Genet. 2006, 120, 410–419. 
46. Lek, A.; Evesson, F.J.; Lemckert, F.A.; Redpath, G.M.I.; Lueders, A.-K.; Turnbull, L.; Whitchurch, C.B.; 
North, K.N.; Cooper, S.T. Calpains, cleaved mini-dysferlinC72, and L-type channels underpin calcium-
dependent muscle membrane repair. J. Neurosci. 2013, 33, 5085–5094. 
47. Redpath, G.M.I.; Woolger, N.; Piper, A.K.; Lemckert, F.A.; Lek, A.; Greer, P.A.; North, K.N.; Cooper, S.T. 
Calpain cleavage within dysferlin exon 40a releases a synaptotagmin-like module for membrane repair. 
Mol. Biol. Cell. 2014, 25, 3037–3048. 
48. O’Connor, V.; Lee, A.G. Synaptic vesicle fusion and synaptotagmin: 2B or not 2B? Nat. Neurosci. 2002, 5, 
823–824. 
Cells 2019, 8, 954 17 of 21 
 
49. Przybylski, R.J.; Szigeti, V.; Davidheiser, S.; Kirby, A.C. Calcium regulation of skeletal myogenesis. II. 
Extracellular and cell surface effects. Cell Calcium 1994, 15, 132–142. 
50. Demonbreun, A.R.; Posey, A.D.; Heretis, K.; Swaggart, K.A.; Earley, J.U.; Pytel, P.; McNally, E.M. Myoferlin 
is required for insulin-like growth factor response and muscle growth. FASEB J. 2010, 24, 1284–1295. 
51. Zhou, Y.; Xiong, L.; Zhang, Y.; Yu, R.; Jiang, X.; Xu, G. Quantitative proteomics identifies myoferlin as a 
novel regulator of A Disintegrin and Metalloproteinase 12 in HeLa cells. J. Proteom. 2016, 148, 94–104. 
52. Galliano, M.F.; Huet, C.; Frygelius, J.; Polgren, A.; Wewer, U.M.; Engvall, E. Binding of ADAM12, a marker 
of skeletal muscle regeneration, to the muscle-specific actin-binding protein, α-actinin-2, is required for 
myoblast fusion. J. Biol. Chem. 2000, 275, 13933–13939. 
53. Posey, A.D.; Pytel, P.; Gardikiotes, K.; Demonbreun, A.R.; Rainey, M.; George, M.; Band, H.; McNally, E.M. 
Endocytic recycling proteins EHD1 and EHD2 interact with fer-1-like-5 (Fer1L5) and mediate myoblast 
fusion. J. Biol. Chem. 2011, 286, 7379–7388. 
54. Roux, I.; Safieddine, S.; Nouvian, R.; Grati, M.; Simmler, M.-C.; Bahloul, A.; Perfettini, I.; Le Gall, M.; 
Rostaing, P.; Hamard, G.; et al. Otoferlin, defective in a human deafness form, is essential for exocytosis at 
the auditory ribbon synapse. Cell 2006, 127, 277–289. 
55. Chapman, E.R.; Hanson, P.I.; An, S.; Jahn, R. Ca2+ regulates the interaction between synaptotagmin and 
syntaxin 1. J. Biol. Chem. 1995, 270, 23667–23671. 
56. Mohrmann, R.; de Wit, H.; Connell, E.; Pinheiro, P.S.; Leese, C.; Bruns, D.; Davletov, B.; Verhage, M.; 
Sørensen, J.B. Synaptotagmin interaction with SNAP-25 governs vesicle docking, priming, and fusion 
triggering. J. Neurosci. 2013, 33, 14417–14430. 
57. Ramakrishnan, N.A.; Drescher, M.J.; Drescher, D.G. Direct interaction of otoferlin with syntaxin 1A, SNAP-
25, and the L-type voltage-gated calcium channel Cav1.3. J. Biol. Chem. 2009, 284, 1364–1372. 
58. Ramakrishnan, N.A.; Drescher, M.J.; Morley, B.J.; Kelley, P.M.; Drescher, D.G. Calcium regulates molecular 
interactions of otoferlin with soluble NSF attachment protein receptor (SNARE) proteins required for hair 
cell exocytosis. J. Biol. Chem. 2014, 289, 8750–8766. 
59. Hams, N.; Padmanarayana, M.; Qiu, W.; Johnson, C.P. Otoferlin is a multivalent calcium-sensitive scaffold 
linking SNAREs and calcium channels. Proc. Natl. Acad. Sci. USA 2017, 114, 8023–8028. 
60. Sharma, A.; Yu, C.; Leung, C.; Trane, A.; Lau, M.; Utokaparch, S.; Shaheen, F.; Sheibani, N.; Bernatchez, P. 
A new role for the muscle repair protein dysferlin in endothelial cell adhesion and angiogenesis. Arterioscler. 
Thromb. Vasc. Biol. 2010, 30, 2196–2204. 
61. Yu, C.; Sharma, A.; Trane, A.; Utokaparch, S.; Leung, C.; Bernatchez, P. Myoferlin gene silencing decreases 
Tie-2 expression in vitro and angiogenesis in vivo. Vascul. Pharmacol. 2011, 55, 26–33. 
62. Bernatchez, P.N.; Sharma, A.; Kodaman, P.; Sessa, W.C. Myoferlin is critical for endocytosis in endothelial 
cells. Am. J. Physiol. Cell. Physiol. 2009, 297, C484–C492. 
63. Han, W.Q.; Xia, M.; Xu, M.; Boini, K.M.; Ritter, J.K.; Li, N.J.; Li, P.L. Lysosome fusion to the cell membrane 
is mediated by the dysferlin C2A domain in coronary arterial endothelial cells. J. Cell Sci. 2012, 125, 1225–
1234. 
64. Leung, C.; Shaheen, F.; Bernatchez, P.; Hackett, T.-L. Expression of myoferlin in human airway epithelium 
and its role in cell adhesion and zonula occludens-1 expression. PLoS ONE 2012, 7, e40478. 
65. Stamer, W.D.; Hoffman, E.A.; Luther, J.M.; Hachey, D.L.; Schey, K.L. Protein profile of exosomes from 
trabecular meshwork cells. J. Proteom. 2011, 74, 796–804. 
66. Iacobuzio-Donahue, C.A.; Maitra, A.; Shen-Ong, G.L.; van Heek, T.; Ashfaq, R.; Meyer, R.; Walter, K.; Berg, 
K.; Hollingsworth, M.A.; Cameron, J.L.; et al. Discovery of Novel Tumor Markers of Pancreatic Cancer 
using Global Gene Expression Technology. Am. J. Pathol. 2002, 160, 1239–1249. 
67. Han, H.; Bearss, D.J.; Browne, L.W.; Calaluce, R.; Nagle, R.B.; Von Hoff, D.D. Identification of differentially 
expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 2002, 62, 2890–2896. 
68. Amatschek, S.; Koenig, U.; Auer, H.; Steinlein, P.; Pacher, M.; Gruenfelder, A.; Dekan, G.; Vogl, S.; Kubista, 
E.; Heider, K.-H.; et al. Tissue-wide expression profiling using cDNA subtraction and microarrays to 
identify tumor-specific genes. Cancer Res. 2004, 64, 844–856. 
69. Yadav, A.; Kumar, B.; Lang, J.C.; Teknos, T.N.; Kumar, P. A muscle-specific protein “myoferlin” modulates 
IL-6/STAT3 signaling by chaperoning activated STAT3 to nucleus. Oncogene 2017, 36, 6374–6382. 
70. McKinney, K.Q.; Lee, Y.Y.; Choi, H.S.; Groseclose, G.; Iannitti, D.A.; Martinie, J.B.; Russo, M.W.; Lundgren, 
D.H.; Han, D.K.; Bonkovsky, H.L.; et al. Discovery of putative pancreatic cancer biomarkers using 
subcellular proteomics. J. Proteom. 2011, 74, 79–88. 
Cells 2019, 8, 954 18 of 21 
 
71. Turtoi, A.; Musmeci, D.; Wang, Y.; Dumont, B.; Somja, J.; Bevilacqua, G.; De Pauw, E.; Delvenne, P.; 
Castronovo, V. Identification of novel accessible proteins bearing diagnostic and therapeutic potential in 
human pancreatic ductal adenocarcinoma. J. Proteome Res. 2011, 10, 4302–4313. 
72. McKinney, K.Q.; Lee, J.-G.; Sindram, D.; Russo, M.W.; Han, D.K.; Bonkovsky, H.L.; Hwang, S.-I. 
Identification of differentially expressed proteins from primary versus metastatic pancreatic cancer cells 
using subcellular proteomics. Cancer Genom. Proteom. 2012, 9, 257–263. 
73. Wang, W.S.; Liu, X.H.; Liu, L.X.; Lou, W.H.; Jin, D.Y.; Yang, P.Y.; Wang, X.L. ITRAQ-based quantitative 
proteomics reveals myoferlin as a novel prognostic predictor in pancreatic adenocarcinoma. J. Proteom. 
2013, 91, 453–465. 
74. Adam, P.J.; Boyd, R.; Tyson, K.L.; Fletcher, G.C.; Stamps, A.; Hudson, L.; Poyser, H.R.; Redpath, N.; 
Griffiths, M.; Steers, G.; et al. Comprehensive proteomic analysis of breast cancer cell membranes reveals 
unique proteins with potential roles in clinical cancer. J. Biol. Chem. 2003, 278, 6482–6489. 
75. Leung, C.; Yu, C.; Lin, M.I.; Tognon, C.; Bernatchez, P. Expression of myoferlin in human and murine 
carcinoma tumors: Role in membrane repair, cell proliferation, and tumorigenesis. Am. J. Pathol. 2013, 182, 
1900–1909. 
76. Hermanns, C.; Hampl, V.; Holzer, K.; Aigner, A.; Penkava, J.; Frank, N.; Martin, D.E.; Maier, K.C.; 
Waldburger, N.; Roessler, S.; et al. The novel MKL target gene myoferlin modulates expansion and 
senescence of hepatocellular carcinoma. Oncogene 2017, 36, 3464–3476. 
77. Kumar, B.; Brown, N.V.; Swanson, B.J.; Schmitt, A.C.; Old, M.; Ozer, E.; Agrawal, A.; Schuller, D.E.; Teknos, 
T.N.; Kumar, P. High expression of myoferlin is associated with poor outcome in oropharyngeal squamous 
cell carcinoma patients and is inversely associated with HPV-status. Oncotarget 2016, 7, 18665–18677. 
78. Song, D.H.; Ko, G.H.; Lee, J.H.; Lee, J.S.; Yang, J.W.; Kim, M.H.; An, H.J.; Kang, M.H.; Jeon, K.N.; Kim, D.C. 
Prognostic role of myoferlin expression in patients with clear cell renal cell carcinoma. Oncotarget 2017, 8, 
89033–89039. 
79. Koh, H.M.; An, H.J.; Ko, G.H.; Lee, J.H.; Lee, J.S.; Kim, D.C.; Seo, D.H.; Song, D.H. Identification of 
Myoferlin Expression for Prediction of Subsequent Primary Malignancy in Patients With Clear Cell Renal 
Cell Carcinoma. In Vivo 2019, 33, 1103–1108. 
80. Kim, M.H.; Song, D.H.; Ko, G.H.; Lee, J.H.; Kim, D.C.; Yang, J.W.; Lee, H.I.; An, H.J.; Lee, J.S. Myoferlin 
expression and its correlation with FIGO histologic grading in early-stage endometrioid carcinoma. J. Pathol. 
Transl. Med. 2018, 52, 93–97. 
81. Welton, J.L.; Khanna, S.; Giles, P.J.; Brennan, P.; Brewis, I.A.; Staffurth, J.; Mason, M.D.; Clayton, A. 
Proteomics analysis of bladder cancer exosomes. Mol. Cell. Proteom. 2010, 9, 1324–1338. 
82. Mathivanan, S.; Lim, J.W.E.; Tauro, B.J.; Ji, H.; Moritz, R.L.; Simpson, R.J. Proteomics analysis of A33 
immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-
specific protein signature. Mol. Cell. Proteom. 2010, 9, 197–208. 
83. Beckler, M.D.; Higginbotham, J.N.; Franklin, J.L.; Ham, A.-J.; Halvey, P.J.; Imasuen, I.E.; Whitwell, C.; Li, 
M.; Liebler, D.C.; Coffey, R.J. Proteomic analysis of exosomes from mutant KRAS colon cancer cells 
identifies intercellular transfer of mutant KRAS. Mol. Cell. Proteom. 2013, 12, 343–355. 
84. Ji, H.; Greening, D.W.; Barnes, T.W.; Lim, J.W.; Tauro, B.J.; Rai, A.; Xu, R.; Adda, C.; Mathivanan, S.; Zhao, 
W.; et al. Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer 
cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics 
2013, 13, 1672–1686. 
85. Choi, D.-S.; Choi, D.-Y.; Hong, B.S.; Jang, S.C.; Kim, D.-K.; Lee, J.; Kim, Y.-K.; Kim, K.P.; Gho, Y.S. 
Quantitative proteomics of extracellular vesicles derived from human primary and metastatic colorectal 
cancer cells. J. Extracell. Vesicles 2012, 1, 18704. 
86. Liang, B.; Peng, P.; Chen, S.; Li, L.; Zhang, M.; Cao, D.; Yang, J.; Li, H.; Gui, T.; Li, X.; Shen, K. 
Characterization and proteomic analysis of ovarian cancer-derived exosomes. J. Proteom. 2013, 80, 171–182. 
87. Sandvig, K.; Llorente, A. Proteomic analysis of microvesicles released by the human prostate cancer cell 
line PC-3. Mol. Cell. Proteom. 2012, 11, M111-012914. 
88. Blomme, A.; Fahmy, K.; Peulen, O.J.; Costanza, B.; Fontaine, M.; Struman, I.; Baiwir, D.; De Pauw, E.; Thiry, 
M.; Bellahcène, A.; et al. Myoferlin is a novel exosomal protein and functional regulator of cancer-derived 
exosomes. Oncotarget 2016, 7, 83669–83683. 
Cells 2019, 8, 954 19 of 21 
 
89. Lawrence, M.S.; Stojanov, P.; Mermel, C.H.; Robinson, J.T.; Garraway, L.A.; Golub, T.R.; Meyerson, M.; 
Gabriel, S.B.; Lander, E.S.; Getz, G. Discovery and saturation analysis of cancer genes across 21 tumour 
types. Nature 2014, 505, 495–501. 
90. Anaya, J. OncoLnc: Linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Comp. Sci. 2016, 
2, e67. 
91. Tang, H.; Wei, P.; Chang, P.; Li, Y.; Yan, D.; Liu, C.; Hassan, M.; Li, D. Genetic polymorphisms associated 
with pancreatic cancer survival: A genome-wide association study. Int. J. Cancer 2017, 141, 678–686. 
92. Ding, F.; Tang, H.; Nie, D.; Xia, L. Long non-coding RNA Fer-1-like family member 4 is overexpressed in 
human glioblastoma and regulates the tumorigenicity of glioma cells. Oncol. Lett. 2017, 14, 2379–2384. 
93. Xia, L.; Nie, D.; Wang, G.; Sun, C.; Chen, G. FER1L4/miR-372/E2F1 works as a ceRNA system to regulate 
the proliferation and cell cycle of glioma cells. J. Cell. Mol. Med. 2019, 23, 3224–3233. 
94. You, Z.; Ge, A.; Pang, D.; Zhao, Y.; Xu, S. Long noncoding RNA FER1L4 acts as an oncogenic driver in 
human pan-cancer. J. Cell. Physiol. 2019, 1859, 46. 
95. Chen, Z.-X.; Chen, C.-P.; Zhang, N.; Wang, T.-X. Low-expression of lncRNA FER1L4 might be a prognostic 
marker in osteosarcoma. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 2310–2314. 
96. Song, H.; Sun, W.; Ye, G.; Ding, X.; Liu, Z.; Zhang, S.; Xia, T.; Xiao, B.; Xi, Y.; Guo, J. Long non-coding RNA 
expression profile in human gastric cancer and its clinical significances. J. Transl. Med. 2013, 11, 225. 
97. Kong, Y.; Ren, Z. Overexpression of LncRNA FER1L4 in endometrial carcinoma is associated with 
favorable survival outcome. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 8113–8118. 
98. Eisenberg, M.C.; Kim, Y.; Li, R.; Ackerman, W.E.; Kniss, D.A.; Friedman, A. Mechanistic modeling of the 
effects of myoferlin on tumor cell invasion. Proc. Natl. Acad. Sci. USA 2011, 108, 20078–20083. 
99. Li, R.; Ackerman, W.E.; Mihai, C.; Volakis, L.I.; Ghadiali, S.; Kniss, D.A. Myoferlin depletion in breast cancer 
cells promotes mesenchymal to epithelial shape change and stalls invasion. PLoS ONE 2012, 7, e39766. 
100. Volakis, L.I.; Li, R.; Ackerman, W.E.; Mihai, C.; Bechel, M.; Summerfield, T.L.; Ahn, C.S.; Powell, H.M.; 
Zielinski, R.; Rosol, T.J.; et al. Loss of myoferlin redirects breast cancer cell motility towards collective 
migration. PLoS ONE 2014, 9, e86110. 
101. Blackstone, B.N.; Li, R.; Ackerman, W.E.; Ghadiali, S.N.; Powell, H.M.; Kniss, D.A. Myoferlin depletion 
elevates focal adhesion kinase and paxillin phosphorylation and enhances cell-matrix adhesion in breast 
cancer cells. Am. J. Physiol. Cell. Physiol. 2015, 308, C642–C649. 
102. Barnhouse, V.R.; Weist, J.L.; Shukla, V.C.; Ghadiali, S.N.; Kniss, D.A.; Leight, J.L. Myoferlin regulates 
epithelial cancer cell plasticity and migration through autocrine TGF-β1 signaling. Oncotarget 2018, 9, 
19209–19222. 
103. Zhang, W.; Zhou, P.; Meng, A.; Zhang, R.; Zhou, Y. Down-regulating Myoferlin inhibits the vasculogenic 
mimicry of melanoma via decreasing MMP-2 and inducing mesenchymal-to-epithelial transition. J. Cell. 
Mol. Med. 2017, 155, 739. 
104. Turtoi, A.; Blomme, A.; Bellahcène, A.; Gilles, C.; Hennequière, V.; Peixoto, P.; Bianchi, E.; Noël, A.; De 
Pauw, E.; Lifrange, E.; et al. Myoferlin is a key regulator of EGFR activity in breast cancer. Cancer Res. 2013, 
73, 5438–5448. 
105. Nylandsted, J.; Becker, A.C.; Bunkenborg, J.; Andersen, J.S.; Dengjel, J.; Jäättelä, M. ErbB2-associated 
changes in the lysosomal proteome. Proteomics 2011, 11, 2830–2838. 
106. Örtegren, U.; Aboulaich, N.; Öst, A.; Strålfors, P. A new role for caveolae as metabolic platforms. Trends 
Endocrinol. Metab. 2007, 18, 344–349. 
107. Blomme, A.; Costanza, B.; de Tullio, P.; Thiry, M.; Van Simaeys, G.; Boutry, S.; Doumont, G.; Di Valentin, 
E.; Hirano, T.; Yokobori, T.; et al. Myoferlin regulates cellular lipid metabolism and promotes metastases 
in triple-negative breast cancer. Oncogene 2017, 36, 2116–2130. 
108. Piper, A.-K.; Ross, S.E.; Redpath, G.M.; Lemckert, F.A.; Woolger, N.; Bournazos, A.; Greer, P.A.; Sutton, 
R.B.; Cooper, S.T. Enzymatic cleavage of myoferlin releases a dual C2-domain module linked to ERK 
signalling. Cell. Signal. 2017, 33, 30–40. 
109. Fahmy, K.; Gonzalez, A.; Arafa, M.; Peixoto, P.; Bellahcène, A.; Turtoi, A.; Delvenne, P.; Thiry, M.; 
Castronovo, V.; Peulen, O.J. Myoferlin plays a key role in VEGFA secretion and impacts tumor-associated 
angiogenesis in human pancreas cancer. Int. J. Cancer 2016, 138, 652–663. 
110. Rademaker, G.; Hennequière, V.; Brohée, L.; Nokin, M.-J.; Lovinfosse, P.; Durieux, F.; Gofflot, S.; Bellier, J.; 
Costanza, B.; Herfs, M.; et al. Myoferlin controls mitochondrial structure and activity in pancreatic ductal 
adenocarcinoma, and affects tumor aggressiveness. Oncogene 2018, 66, 1–15. 
Cells 2019, 8, 954 20 of 21 
 
111. Rademaker, G.; Costanza, B.; Bellier, J.; Herfs, M.; Peiffer, R.; Agirman, F.; Maloujahmoum, N.; Habraken, 
Y.; Delvenne, P.; Bellahcène, A.; et al. Human colon cancer cells highly express myoferlin to maintain a fit 
mitochondrial network and escape p53-driven apoptosis. Oncogenesis 2019, 8, 21. 
112. LeBleu, V.S.; O’Connell, J.T.; Gonzalez Herrera, K.N.; Wikman, H.; Pantel, K.; Haigis, M.C.; de Carvalho, 
F.M.; Damascena, A.; Domingos Chinen, L.T.; Rocha, R.M.; et al. PGC-1α mediates mitochondrial 
biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 2014, 16, 992–
1003. 
113. Porporato, P.E.; Payen, V.L.; Pérez-Escuredo, J.; De Saedeleer, C.J.; Danhier, P.; Copetti, T.; Dhup, S.; Tardy, 
M.; Vazeille, T.; Bouzin, C.; et al. A mitochondrial switch promotes tumor metastasis. Cell Rep. 2014, 8, 754–
766. 
114. Rademaker, G.; Costanza, B.; Anania, S.; Agirman, F.; Maloujahmoum, N.; Di Valentin, E.; Goval, J.J.; 
Bellahcène, A.; Castronovo, V.; Peulen, O.J. Myoferlin Contributes to the Metastatic Phenotype of 
Pancreatic Cancer Cells by Enhancing Their Migratory Capacity through the Control of Oxidative 
Phosphorylation. Cancers 2019, 11, 853. 
115. Majumder, S.; Raimondo, M.; Taylor, W.R.; Yab, T.C.; Berger, C.K.; Dukek, B.A.; Cao, X.; Foote, P.H.; Wu, 
C.W.; Devens, M.E.; et al.; Ahlquist, D.A. Methylated DNA in Pancreatic Juice Distinguishes Patients with 
Pancreatic Cancer From Controls. Clin. Gastroenterol. Hepatol. 2019. doi:10.1016/j.cgh.2019.07.017. 
116. Song, D.H.; Ko, G.H.; Lee, J.H.; Lee, J.S.; Lee, G.-W.; Kim, H.C.; Yang, J.W.; Heo, R.W.; Roh, G.S.; Han, S.-
Y.; et al. Myoferlin expression in non-small cell lung cancer: Prognostic role and correlation with VEGFR-
2 expression. Oncol. Lett. 2016, 11, 998–1006. 
117. Gao, X.; Wang, N.; Wu, S.; Cui, H.; An, X.; Yang, Y. Long non-coding RNA FER1L4 inhibits cell proliferation 
and metastasis through regulation of the PI3K/AKT signaling pathway in lung cancer cells. Mol. Med. Rep. 
2019, 20, 182–190. 
118. Ma, L.; Zhang, L.; Guo, A.; Liu, L.C.; Yu, F.; Diao, N.; Xu, C.; Wang, D. Overexpression of FER1L4 promotes 
the apoptosis and suppresses epithelial-mesenchymal transition and stemness markers via activating 
PI3K/AKT signaling pathway in osteosarcoma cells. Pathol. Res. Pract. 2019, 215, 152412. 
119. Ma, W.; Zhang, C.-Q.; Li, H.-L.; Gu, J.; Miao, G.-Y.; Cai, H.-Y.; Wang, J.-K.; Zhang, L.-J.; Song, Y.-M.; Tian, 
Y.-H.; et al. LncRNA FER1L4 suppressed cancer cell growth and invasion in esophageal squamous cell 
carcinoma. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 2638–2645. 
120. Wang, X.; Dong, K.; Jin, Q.; Ma, Y.; Yin, S.; Wang, S. Upregulation of lncRNA FER1L4 suppresses the 
proliferation and migration of the hepatocellular carcinoma via regulating PI3K/AKT signal pathway. J. 
Cell. Biochem. 2019, 120, 6781–6788. 
121. Liu, Z.; Shao, Y.; Tan, L.; Shi, H.; Chen, S.; Guo, J. Clinical significance of the low expression of FER1L4 in 
gastric cancer patients. Tumour Biol. 2014, 35, 9613–9617. 
122. Xia, T.; Chen, S.; Jiang, Z.; Shao, Y.; Jiang, X.; Li, P.; Xiao, B.; Guo, J. Long noncoding RNA FER1L4 
suppresses cancer cell growth by acting as a competing endogenous RNA and regulating PTEN expression. 
Sci. Rep. 2015, 5, 13445. 
123. Xia, T.; Liao, Q.; Jiang, X.; Shao, Y.; Xiao, B.; Xi, Y.; Guo, J. Long noncoding RNA associated-competing 
endogenous RNAs in gastric cancer. Sci. Rep. 2014, 4, 6088. 
124. Salmena, L.; Poliseno, L.; Tay, Y.; Kats, L.; Pandolfi, P.P. A ceRNA hypothesis: The rosetta stone of a hidden 
RNA language? Cell 2011, 146, 353–358. 
125. Yue, B.; Sun, B.; Liu, C.; Zhao, S.; Zhang, D.; Yu, F.; Yan, D. Long non-coding RNA Fer-1-like protein 4 
suppresses oncogenesis and exhibits prognostic value by associating with miR-106a-5p in colon cancer. 
Cancer Sci. 2015, 106, 1323–1332. 
126. Wu, J.; Huang, J.; Wang, W.; Xu, J.; Yin, M.; Cheng, N.; Yin, J. Long non-coding RNA Fer-1-like protein 4 
acts as a tumor suppressor via miR-106a-5p and predicts good prognosis in hepatocellular carcinoma. 
Cancer Biomark. 2017, 20, 55–65. 
127. Fei, D.; Zhang, X.; Liu, J.; Tan, L.; Xing, J.; Zhao, D.; Zhang, Y. Long Noncoding RNA FER1L4 Suppresses 
Tumorigenesis by Regulating the Expression of PTEN Targeting miR-18a-5p in Osteosarcoma. Cell. Physiol. 
Biochem. 2018, 51, 1364–1375. 
128. Liu, S.; Zou, B.; Tian, T.; Luo, X.; Mao, B.; Zhang, X.; Lei, H. Overexpression of the lncRNA FER1L4 inhibits 
paclitaxel tolerance of ovarian cancer cells via the regulation of the MAPK signaling pathway. J. Cell. 
Biochem. 2018, 120, 7581–7589. 
129. Théry, C. Cancer: Diagnosis by extracellular vesicles. Nature 2015, 523, 161–162. 
Cells 2019, 8, 954 21 of 21 
 
130. Ciardiello, C.; Cavallini, L.; Spinelli, C.; Yang, J.; Reis-Sobreiro, M.; de Candia, P.; Minciacchi, V.R.; Di Vizio, 
D. Focus on Extracellular Vesicles: New Frontiers of Cell-to-Cell Communication in Cancer. Int. J. Mol. Sci. 
2016, 17, 175. 
131. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. 
132. Anderson, R.G.; Ghiraldeli, L.P.; Pardee, T.S. Mitochondria in cancer metabolism, an organelle whose time 
has come? Biochim. Biophys. Acta Rev. Cancer 2018, 1870, 96–102. 
133. Zhang, T.; Jingjie, L.; He, Y.; Yang, F.; Hao, Y.; Jin, W.; Wu, J.; Sun, Z.; Li, Y.; Chen, Y.; Yi, Z.; Liu, M. A small 
molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer. Nat. Commun. 2018, 9, 
3726. 
134. Li, Y.; He, Y.; Shao, T.; Pei, H.; Guo, W.; Mi, D.; Krimm, I.; Zhang, Y.; Wang, P.; Wang, X.; et al. Modification 
and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against 
Pancreatic Cancer Metastasis through Targeting Myoferlin. J. Med. Chem. 2019, 62, 4949–4966. 
135. Sondergaard, P.C.; Griffin, D.A.; Pozsgai, E.R.; Johnson, R.W.; Grose, W.E.; Heller, K.N.; Shontz, K.M.; 
Montgomery, C.L.; Liu, J.; Clark, K.R.; et al. AAV.Dysferlin Overlap Vectors Restore Function in 
Dysferlinopathy Animal Models. Ann. Clin. Transl. Neurol. 2015, 2, 256–270. 
136. Escobar, H.; Schöwel, V.; Spuler, S.; Marg, A.; Izsvák, Z. Full-length Dysferlin Transfer by the Hyperactive 
Sleeping Beauty Transposase Restores Dysferlin-deficient Muscle. Mol. Ther. Nucleic Acids 2016, 5, e277. 
137. Potter, R.A.; Griffin, D.A.; Sondergaard, P.C.; Johnson, R.W.; Pozsgai, E.R.; Heller, K.N.; Peterson, E.L.; 
Lehtimäki, K.K.; Windish, H.P.; Mittal, P.J.; et al. Systemic Delivery of Dysferlin Overlap Vectors Provides 
Long-Term Gene Expression and Functional Improvement for Dysferlinopathy. Hum. Gene Ther. 2017, 
hum.2017.062. 
138. Llanga, T.; Nagy, N.; Conatser, L.; Dial, C.; Sutton, R.B.; Hirsch, M.L. Structure-Based Designed Nano-
Dysferlin Significantly Improves Dysferlinopathy in BLA/J Mice. Mol. Ther. 2017, 25, 2150–2162. 
139. Lee, J.H.; Kim, Y.; Yoon, Y.-E.; Kim, Y.-J.; Oh, S.-G.; Jang, J.-H.; Kim, E. Development of efficient adeno-
associated virus (AAV)-mediated gene delivery system with a phytoactive material for targeting human 
melanoma cells. New Biotechnol. 2017, 37, 194–199. 
140. Chow, R.D.; Guzman, C.D.; Wang, G.; Schmidt, F.; Youngblood, M.W.; Ye, L.; Errami, Y.; Dong, M.B.; 
Martinez, M.A.; Zhang, S.; et al. AAV-mediated direct in vivo CRISPR screen identifies functional 
suppressors in glioblastoma. Nat. Neurosci. 2017, 20, 1329–1341. 
141. Hodge, R.; Narayanavari, S.A.; Izsvák, Z.; Ivics, Z. Wide Awake and Ready to Move: 20 Years of Non-Viral 
Therapeutic Genome Engineering with the Sleeping Beauty Transposon System. Hum. Gene Ther. 2017, 28, 
842–855. 
 
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
 
